| Filed On | Filing |
|---|---|
| 05 Feb 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation
(b)Departure of Douglas Manion as Chief Executive Officer and President and Director |
| 18 Jan 2019 |
8-K/A: Financial Statements and Exhibits
These unaudited pro forma condensed combined financial statements of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) are presented to illustrate the estimated effects of the acquisition of RHOFADE (oxymetazoline hydrochloride) cr... |
Loading...